Human MMP13 ELISA Kit (ab221839)
Key features and details
- Sensitivity: 5.7 pg/ml
- Range: 39 pg/ml - 2500 pg/ml
- Sample type: Cell culture media, Saliva, Serum, Urine
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Cow, Human, Pig
Product nameHuman MMP13 ELISA Kit
See all MMP13 kits
Intra-assay Sample n Mean SD CV% Supernatant 8 5.9% Inter-assay Sample n Mean SD CV% Supernatant 3 5%
Sample typeSaliva, Urine, Serum, Cell culture media
Assay typeSandwich (quantitative)
Range39 pg/ml - 2500 pg/ml
Sample specific recovery Sample type Average % Range Saliva 80 78% - 82% Urine 84 74% - 93% Serum 83 78% - 88% Cell culture media 102 101% - 103%
Assay time2h 30m
Assay durationMultiple steps standard assay
Species reactivityReacts with: Cow, Human, Pig
Human MMP13 ELISA Kit (ab221839) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of MMP13 protein in saliva, serum, urine, and cell culture media. It uses our proprietary SimpleStep ELISA® technology. Quantitate Human MMP13 with 5.7 pg/ml sensitivity.
SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:
- Single-wash protocol
- High sensitivity, specificity and reproducibility from superior antibodies
- Fully validated in biological samples
- 96-wells plate breakable into 12 x 8 wells strips
A 384-well SimpleStep ELISA® microplate (ab203359) is available to use as an alternative to the 96-well microplate provided with SimpleStep ELISA® kits.
Human MMP-13, matrix metallopeptidase 13, also known as Collagenase 3 is a secreted protein encoded by the gene MMP13. MMP-13 belongs to the matrix metalloproteinase family, which are calcium dependent endopeptidases. MMP-13 degrades type I, II, and III collagen. The MMP protein-13 is expressed as an inactive pro-form composed of an 83-amino acid pro-peptide, an amino acid catalytic domain, and hemopexin-like domain. Dissociation of a zinc ion from the cysteine-switch motif releases the activation-peptide, thus activating the enzyme. MMP-13 is involved in various processes, such as, embryonic development, ossification, wound healing, and tissue remolding.
PlatformMicroplate (12 x 8 well strips)
Storage instructionsStore at +4°C. Please refer to protocols.
Components 1 x 96 tests 10X Human MMP-13 Capture Antibody 1 x 600µl 10X Human MMP-13 Detector Antibody 1 x 600µl 10X Wash Buffer PT (ab206977) 1 x 20ml Antibody Diluent 4BI 1 x 6ml Human MMP-13 Lyophilized Recombinant Protein 1 x 2 vials Plate Seals 1 unit Sample Diluent NS (ab193972) 2 x 50ml SimpleStep Pre-Coated 96-Well Microplate (ab206978) 1 unit Stop Solution 1 x 12ml Streptavidin-HRP 1 x 100µl TMB Development Solution 1 x 12ml
FunctionDegrades collagen type I. Does not act on gelatin or casein. Could have a role in tumoral process.
Tissue specificitySeems to be specific to breast carcinomas.
Involvement in diseaseDefects in MMP13 are the cause of spondyloepimetaphyseal dysplasia Missouri type (SEMD-MO) [MIM:602111]. A bone disease characterized by moderate to severe metaphyseal changes, mild epiphyseal involvement, rhizomelic shortening of the lower limbs with bowing of the femora and/or tibiae, coxa vara, genu varum and pear-shaped vertebrae in childhood. Epimetaphyseal changes improve with age.
Defects in MMP13 are the cause of metaphyseal anadysplasia type 1 (MANDP1) [MIM:602111]. Metaphyseal anadysplasia consists of an abnormal bone development characterized by severe skeletal changes that, in contrast with the progressive course of most other skeletal dysplasias, resolve spontaneously with age. Clinical characteristics are evident from the first months of life and include slight shortness of stature and a mild varus deformity of the legs. Patients attain a normal stature in adolescence and show improvement or complete resolution of varus deformity of the legs and rhizomelic micromelia.
Sequence similaritiesBelongs to the peptidase M10A family.
Contains 4 hemopexin-like domains.
DomainThe conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
Cellular localizationSecreted > extracellular space > extracellular matrix.
- Information by UniProt
- CLG 3
- Collagenase 3
- Entrez Gene: 281914 Cow
- Entrez Gene: 4322 Human
- Entrez Gene: 397346 Pig
- Omim: 600108 Human
- SwissProt: O77656 Cow
- SwissProt: P45452 Human
- Unigene: 2936 Human
Background-subtracted data values (mean +/- SD) are graphed.
The concentrations of MMP-13 were measured in duplicates, interpolated from the MMP-13 standard curves and corrected for sample dilution. Undiluted samples are as follows: serum 50%, saliva 50%, urine 50%, and RPMI media 50%. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2).
Interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean MMP-13 concentration was determined to be 32 pg/mL with a range of N.D. – 142 pg/mL.
To learn more about the advantages of recombinant antibodies see here.
Datasheets and documents
ab221839 has been referenced in 2 publications.
- Nairon KG et al. Tumor cell-conditioned media drives collagen remodeling via fibroblast and pericyte activation in an in vitro premetastatic niche model. iScience 25:104645 (2022). PubMed: 35811850
- Hu J et al. Peptidomic analysis on synovial tissue reveals galectin-1 derived peptide as a potential bioactive molecule against rheumatoid arthritis. Cytokine 131:155020 (2020). PubMed: 32413706